Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months
The FDA authorized an extension of Symvess expiration dating from 18 months to 36 months when stored refrigerated at 2°C to 8°C, supported by stability data showing the product meets all established quality specifications through the longer period. Humacyte said the doubled shelf life helps hospitals keep Symvess on hand for urgent vascular repairs while simplifying inventory planning and reducing product waste. Founder and CEO Laura Niklason said the authorization supports commercial availability and should further facilitate hospital adoption, ensuring surgeons have access to Symvess when urgent vascular repair is needed.
Key figures
- Storage conditions
- 2°C to 8°C (36°F to 46°F), refrigerated
- Sbla filing expected
- November 2026
- New shelf life months
- 36
- Original fda approval
- December 2024
- Prior shelf life months
- 18
- Second indication sought
- dialysis access
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.